 The FDA has approved Sol-Gel Technologies Ltds NASDAQ: SLGL first proprietary drug product, Twyneo tretinoinbenzoyl peroxide cream, 0.13, indicated for acne vulgaris in adults and pediatric patients nine years of age and older. Twyneo uses Sol-Gels patented technology to entrap tretinoin, a retinoid, and benzoyl peroxide within silica-based microcapsules to stabilize tretinoin from being degraded by benzoyl peroxide and to release each of the active drug ingredients slowly. 